ZimVie Reports Q1 2025 Financial Results with $112M in Net Sales and Reduced Net Loss

ZimVie Inc. reported its financial results for the first quarter of 2025, revealing a net sales figure of $111.997 million, a decrease of 5.2% from $118.195 million in the same period of 2024. The company experienced a net loss of $1.471 million, or $0.05 per share, compared to a net loss of $7.761 million, or $0.29 per share, in the prior year. The improvement in net loss was attributed to a reduction in operating expenses and an increase in other income, primarily from the transition services agreement related to the sale of its spine segment.

The company’s operating profit for the quarter was $780,000, a significant turnaround from an operating loss of $2.732 million in the first quarter of 2024. Total operating expenses decreased to $111.217 million from $120.927 million year-over-year, driven by lower costs of products sold and reductions in selling, general, and administrative expenses. The cost of products sold fell to $37.949 million, representing 33.9% of net sales, down from 37.4% in the previous year, reflecting improved manufacturing efficiencies.

ZimVie completed the sale of its spine segment on April 1, 2024, for a total consideration of $377 million, which has been classified as discontinued operations in the financial statements. The sale allowed the company to focus on its core dental business, which includes a range of dental implant systems and digital dentistry solutions. The company also initiated restructuring activities in January 2024 to optimize its operations post-sale, incurring $1.432 million in related costs during the quarter.

In terms of operational metrics, ZimVie reported an increase in accounts receivable to $76.688 million from $65.211 million at the end of 2024, indicating improved collection efforts. The company’s cash and cash equivalents stood at $66.750 million, down from $74.974 million at the end of the previous fiscal year. ZimVie’s employee headcount remained stable, with 27,921,548 shares of common stock outstanding as of May 5, 2025.

Looking ahead, ZimVie anticipates continued challenges due to market conditions, including pricing pressures and foreign currency fluctuations. The company is focused on enhancing its product offerings and expanding its market presence, particularly in the dental sector. Management remains optimistic about the potential for growth, supported by strategic initiatives and ongoing investments in product development.